Drugs / nab-Palitaxel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05806060 Background | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05760378 Background | Mar 2023 → Jan 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nab-Palitaxel | “nab-palitaxel (Nab-P), and maintained by VEGFR and capecitabine” NCT05806060 ↗ |
| Known as | Nab-P | “nab-palitaxel (Nab-P)” NCT05806060 ↗ |